News

Latest news

Iconovo at Carnegie småbolagsdag

November 28, 2024

Want to learn more about Iconovo? Listen to Johan Wäborg, CEO at Iconovo presenting the company at Carnegie's småbolagsdag. It's streamed live at 11:05…

Redeye: Iconovo company presentation

November 15, 2024

Johan Wäborg, CEO of Iconovo, presented what's going on at Iconovo at the Redeye Theme: Medtech & Diagnostics Event 2024. What's going on? Please…

BIOSTOCK: Inhalationsspecialisterna Iconovo tar in kapital (Swedish only)

November 4, 2024

En intranasal fetmabehandling under utveckling, en generisk utmanare till astmaprodukten Symbicort och samtal med potentiella partners står på agendan…

Press releases

2026 2025 2024 2023 2022 2021 2020 2019 2018

Nov 18, 2024, 19:35

News

IR

English

Regulatory

MAR

Corporate Action

Shares

Issuance

mfn-cus-top-disclaimer

Iconovo announces preliminary outcome of rights issue

Oct 30, 2024, 15:57

News

IR

English

Regulatory

MAR

Corporate Action

Other

Iconovo's partner Amneal has taken the next important step in the clinical development of ICOres® budesonide/formoterol

Oct 30, 2024, 15:57

News

IR

Swedish

Regulatory

MAR

Corporate Action

Other

Iconovos partner Amneal har tagit nästa viktiga steg i den kliniska utvecklingen av ICOres® budesonid/formoterol

Oct 30, 2024, 14:00

News

IR

Swedish

Regulatory

Listing Regulation

Corporate Action

Prospectus

mfn-cus-top-disclaimer

Iconovo offentliggör informationsmemorandum med anledning av förestående företrädesemission samt bjuder in till investerarpresentationer

Oct 30, 2024, 14:00

News

IR

English

Regulatory

Listing Regulation

Corporate Action

Prospectus

mfn-cus-top-disclaimer

Iconovo publishes information memorandum regarding upcoming rights issue and invites to investor presentations

Oct 29, 2024, 11:00

News

IR

Swedish

Regulatory

Listing Regulation

Corporate Information

General meeting

Raport bolagsstämman

Kommuniké från extra bolagsstämma i Iconovo AB den 29 oktober 2024

Oct 24, 2024, 08:30

News

IR

Swedish

Regulatory

MAR

Report

Interim

Q3

KVARTALSRAPPORT Q3 2024

Oct 24, 2024, 08:30

News

IR

English

Regulatory

MAR

Report

Interim

Q3

QUARTERLY REPORT Q3 2024

Sep 25, 2024, 18:05

News

IR

Swedish

Regulatory

Listing Regulation

Corporate Information

General meeting

Notice

Kallelse till extra bolagsstämma i Iconovo AB

Sep 25, 2024, 17:55

News

IR

English

Regulatory

MAR

Corporate Action

Shares

Issuance

mfn-cus-disclaimer

mfn-cus-top-disclaimer

Iconovo decides on a rights issue of units of approximately SEK 28.7 million subject to approval by extraordinary general meeting

Sep 25, 2024, 17:55

News

IR

Swedish

Regulatory

MAR

Corporate Action

Shares

Issuance

mfn-cus-disclaimer

mfn-cus-top-disclaimer

Iconovo beslutar om företrädesemission av units om cirka 28,7 MSEK villkorat av godkännande från extra bolagsstämma

Sep 20, 2024, 09:55

News

IR

Swedish

Corporate Action

Other

Iconovo får positivt utlåtande från FDA gällande utbytbarhet för ICOpre®

Sep 20, 2024, 09:55

News

IR

English

Corporate Action

Other

Iconovo receives positive guidance from FDA regarding substitutability for ICOpre®

Sep 13, 2024, 12:41

News

IR

Swedish

Regulatory

MAR

Corporate Action

Other

Iconovo säger upp samtliga avtal med ISR Immune System Regulation AB och återtar de immateriella rättigheterna till ICOone®

Sep 13, 2024, 12:41

News

IR

English

Regulatory

MAR

Corporate Action

Other

Iconovo terminates all agreements with ISR Immune System Regulation AB and reclaims the intellectual property rights to ICOone®

Sep 10, 2024, 12:45

News

IR

Swedish

Correction

Regulatory

MAR

Corporate Action

Other

Rättelse: Iconovo utvecklar intranasalt inhalerad semaglutid i ICOone Nasal för mer användarvänlig behandling av övervikt och fetma

Sep 10, 2024, 12:45

News

IR

English

Correction

Regulatory

MAR

Corporate Action

Other

Correction: Iconovo develops intranasally inhaled semaglutide in ICOone Nasal for more user-friendly treatment of overweight and obesity

Sep 10, 2024, 10:04

News

IR

English

Regulatory

Listing Regulation

Corporate Action

Other

Iconovo develops intranasally inhaled semaglutide in ICOone Nasal® for more user-friendly treatment of overweight and obesity

Sep 10, 2024, 10:04

News

IR

Swedish

Regulatory

Listing Regulation

Corporate Action

Other

Iconovo utvecklar intranasalt inhalerad semaglutid i ICOone Nasal® för mer användarvänlig behandling av övervikt och fetma

Jul 12, 2024, 08:30

News

IR

Swedish

Regulatory

MAR

Report

Interim

Q2

KVARTALSRAPPORT Q2-2024: ”Ett kvartal med intensiv affärsutveckling och konstruktiva förhandlingar”